CFRX:NSD-ContraFect Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.80

Change

-0.02 (-0.52)%

Market Cap

USD 0.15B

Volume

0.28M

Average Target Price

USD 11.33 (+198.25%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.60 (-2.82%)

USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

-2.11 (-0.98%)

USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

+5.59 (+1.13%)

USD52.92B 16.28 12.68
BNTX BioNTech SE

+18.64 (+10.15%)

USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.38 (+0.81%)

USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

-8.65 (-2.77%)

USD28.69B N/A N/A
SGEN Seagen Inc

-3.56 (-2.55%)

USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

+0.52 (+1.27%)

USD24.87B 22.60 14.92
GMAB Genmab A/S

-0.16 (-0.43%)

USD24.33B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CFRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.75% 28% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.75% 28% F 13% F
Trailing 12 Months  
Capital Gain -39.30% 23% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.30% 23% F 6% F
Trailing 5 Years  
Capital Gain 40.22% 63% D 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.22% 63% D 41% F
Average Annual (5 Year Horizon)  
Capital Gain 307.63% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 307.63% 97% A+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 605.47% 3% F 3% F
Risk Adjusted Return 50.81% 76% C 70% C-
Market Capitalization 0.15B 27% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.80 33% F 50% F
Price/Book Ratio 11.38 18% F 14% F
Price / Cash Flow Ratio -4.53 34% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -199.94% 10% F 5% F
Return on Invested Capital -243.14% 4% F 2% F
Return on Assets -49.70% 14% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.28 56% F 41% F
Short Percent 17.20% 10% F 10% F
Beta 0.93 72% C- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.